경구 보체 저해제 시장 : 약제별, 연령층별, 유통경로별, 유형별, 투여 경로별, 국가별, 지역별 - 세계 업계 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)

Oral Complement Inhibitors Market size was valued at US$ 2,180.7 Million in 2025, expanding at a CAGR of 7.1% from 2026 to 2033.

Oral complement inhibitors are targeted therapies that suppress specific complement proteins via oral administration, with iptacopan being the only orally administered complement inhibitor in the provided portfolio. The indications range from various hematologic, nephrologic, ocular, and immunologic disorders. It is produced through synthetic processes, biologics manufacturing, sterile fill-finish, and drug delivery technologies. Novartis's medicines reached 304 million patients worldwide in 2025. Thus, the market provides a wide range of complement inhibitors for injectable and intravitreal administration, covering similar indications and therapies. Moreover, the market trends towards developing oral therapies for diverse indications while generally favoring single-agent regimens that provide long-term disease control.

Oral Complement Inhibitors Market- Market Dynamics

Selective Pathway Control Is Rewriting Complement-Therapy Positioning

Pathway-selective inhibition is changing complement therapy from broad terminal blockade toward intervention closer to disease biology. Iptacopan targets factor B in the alternative pathway and has shown growth as an oral therapy for a range of diseases, including PNH, IgA nephropathy, and C3G, which are characterized by alternative pathway-driven amplification. With an upstream mechanism of action, iptacopan not only provides an alternative to C5-targeting antibodies but also allows for chronic outpatient therapy. In the Phase III APPEAR-C3G trial, Novartis reported a 35.1% reduction in proteinuria in 2025, supporting the clinical utility of proximal complement inhibition. As the evidence for the therapeutic benefit of pathway-specific approaches emerges, the need for differentiation based on the mechanism of action will become important to market development.

Oral Complement Inhibitors Market- Segmentation Analysis:

The Global Oral Complement Inhibitors Market is segmented on the basis of Drug, Age Group, Distribution, Type, Route of Administration, and Region.

Within the drug category, iptacopan is positioned as the only oral therapy, which addresses the key attribute of the market. Being the first oral inhibitor of factor B, it targets the alternative complement pathway and provides treatment options for both hematological and renal diseases while sparing patients the need for C5-directed therapeutics that require regular infusions. Moreover, in March 2025, the FDA approved Fabhalta for the treatment of C3G, making iptacopan the third complement-mediated disease to be addressed by the drug. Hence, the focus shifts to the oral platform that can offer treatment across a range of complement-mediated diseases rather than targeting individual conditions.

However, other complement inhibitors, including eculizumab, ravulizumab, sutimlimab, pegcetacoplan, and avacincaptad pegol, are expected to retain significant relevance in the broader complement therapeutics market. As of 2025, more than 2,200 patient-years of exposure to pegcetacoplan have been reported across Apellis' approved indications, illustrating the depth of clinical experience with non-oral complement inhibitors. As such, orally administered complement therapeutics will face competition from established agents on both commercial and clinical grounds-with biologics presenting additional practical challenges in terms of interchangeability and biosimilar competition.

Oral Complement Inhibitors Market- Geographical Insights

North America is well positioned in the therapeutics market due to a sophisticated rare disease ecosystem, high levels of care, clinical research, and fast regulatory processes. The U.S. approved Fabhalta for C3G in March 2025, making it the first treatment for the disease and significantly bolstering the market for oral pathway-selective complement inhibitors. In the U.S., EMPAVELI received approval for the treatment of C3G and primary IC-MPGN in July 2025. The approvals in the U.S. in 2025 could significantly impact the market. The key factors for the U.S. leading the market are the influence of its regulatory authorities and the subsequent impact on the clinical development of rival therapeutics, as well as the relevance of the evidence required for the approval process and the implications for the commercialization of later-line treatments.

Europe is an important complement therapy market, dominated by a coordinated regulatory environment, rare-disease patient networks, and critical evaluation of drugs. In February 2025, the EMA's CHMP gave Fabhalta a positive opinion for C3G, while Novartis has noted that half of patients with the disease will develop kidney failure within a decade of diagnosis. Thus, the considerable burden of illness drives demand for disease-modifying treatments, supporting the need for centralized clinical and regulatory oversight. However, reimbursement decisions are nationally differentiated, defining the commercial landscape despite favorable regulatory reviews. Europe therefore functions as a critical validation and access market for selective complement inhibition rather than merely a secondary sales territory.

Oral Complement Inhibitors Market- Competitive Landscape:

The factors that determine competitive dynamics within the oral complement therapeutics market are mechanism of action, route of administration, indication, and evidence of clinical efficacy. Novartis sells Fabhalta, which is administered orally and targets factor B. It competes with AstraZeneca's C5 portfolio and Apellis's C3 inhibitor, pegcetacoplan. Novartis has reported that its drugs were distributed in 118 countries worldwide in 2025. The company has an organized framework for commercializing its pharmaceuticals on a global scale. The other competitive factors that could impact market growth are manufacturing, pharmacovigilance, vaccination, specialty distribution, and patient identification by indications. The competitive landscape is therefore shifting towards diversity of platforms and lifecycle management, with oral selectivity as a key differentiator.

Recent Developments:

In March 2025, the FDA approved Novartis's Fabhalta (iptacopan) for the treatment of adults with C3 glomerulopathy (C3G). Fabhalta became the first and sole therapy for patients with C3G, an ultra-rare kidney disease, which was previously poorly addressed by available treatments.

In July 2025, Apellis Pharmaceuticals announced the approval of its EMPAVELI (pegcetacoplan) for the treatment of C3G and primary IC-MPGN. The Phase III VALIANT study of EMPAVELI showed a 68% decrease in proteinuria along with C3 reduction, stabilization of kidney function, and reduction of C3 deposits.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• Akari Therapeutics, Plc
• Alexion Pharmaceuticals, Inc.
• Apellis Pharmaceuticals, Inc.
• Biocryst Pharmaceuticals, Inc.
• Amgen Inc.
• ChemoCentryx, Inc.
• Ionis Pharmaceuticals, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals, Inc.
• Omeros Corporation
• Roche Holding AG
• Swedish Orphan Biovitrum AB
• Others

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, BY DRUG- MARKET ANALYSIS, 2020 - 2033

• Eculizumab
• Iptacopan
• Sutimlimab
• Ravulizumab
• Pegcetacoplan
• Avacincaptad pegol
• Others

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2020 - 2033

• Adults
• Pediatric

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2020 - 2033

• Drug Stores & Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
• Specialty Pharmacies
• Others

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033

• Biosimilar
• Branded
• Others

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

• Intravenous
• Intravitreal
• Subcutaneous
• Others

GLOBAL ORAL COMPLEMENT INHIBITORS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Denmark
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Taiwan
• Vietnam
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Iran
• Qatar
• Rest of MEA

Table of Contents

1. Oral Complement Inhibitors Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Oral Complement Inhibitors Market Snippet by Drug
  • 2.1.2. Oral Complement Inhibitors Market Snippet by Age Group
  • 2.1.3. Oral Complement Inhibitors Market Snippet by Distribution
  • 2.1.4. Oral Complement Inhibitors Market Snippet by Type
  • 2.1.5. Oral Complement Inhibitors Market Snippet by Route of Administration
  • 2.1.6. Oral Complement Inhibitors Market Snippet by Country
  • 2.1.7. Oral Complement Inhibitors Market Snippet by Region
• 2.2. Competitive Insights

3. Oral Complement Inhibitors Key Market Trends

• 3.1. Oral Complement Inhibitors Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Oral Complement Inhibitors Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Oral Complement Inhibitors Market Opportunities
• 3.4. Oral Complement Inhibitors Market Future Trends

4. Oral Complement Inhibitors Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Oral Complement Inhibitors Market: Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Oral Complement Inhibitors Market Landscape

• 6.1. Oral Complement Inhibitors Market Share Analysis, 2025
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Oral Complement Inhibitors Market - By Drug

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Drug, 2025 & 2033 (%)
  • 7.1.2. Eculizumab
  • 7.1.3. Iptacopan
  • 7.1.4. Sutimlimab
  • 7.1.5. Ravulizumab
  • 7.1.6. Pegcetacoplan
  • 7.1.7. Avacincaptad pegol
  • 7.1.8. Others

8. Oral Complement Inhibitors Market - By Age Group

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Age Group, 2025 & 2033 (%)
  • 8.1.2. Adults
  • 8.1.3. Pediatric

9. Oral Complement Inhibitors Market - By Distribution

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Distribution, 2025 & 2033 (%)
  • 9.1.2. Drug Stores & Retail Pharmacies
  • 9.1.3. Hospital Pharmacies
  • 9.1.4. Online Pharmacies
  • 9.1.5. Specialty Pharmacies
  • 9.1.6. Others

10. Oral Complement Inhibitors Market - By Type

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By Type, 2025 & 2033 (%)
  • 10.1.2. Biosimilar
  • 10.1.3. Branded
  • 10.1.4. Others

11. Oral Complement Inhibitors Market - By Route of Administration

• 11.1. Overview
  • 11.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
  • 11.1.2. Intravenous
  • 11.1.3. Intravitreal
  • 11.1.4. Subcutaneous
  • 11.1.5. Others

12. Oral Complement Inhibitors Market- By Geography

• 12.1. Introduction
  • 12.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
• 12.2. North America
  • 12.2.1. Overview
  • 12.2.2. Oral Complement Inhibitors Key Manufacturers in North America
  • 12.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 12.2.4. North America Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
  • 12.2.5. North America Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
  • 12.2.6. North America Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
  • 12.2.7. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  • 12.2.8. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.2.9. U.S.
    • 12.2.9.1. Overview
    • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.2.9.3. U.S. Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.2.9.4. U.S. Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.2.9.5. U.S. Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.2.9.6. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.2.9.7. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.2.10. Canada
    • 12.2.10.1. Overview
    • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.2.10.3. Canada Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.2.10.4. Canada Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.2.10.5. Canada Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.2.10.6. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.2.10.7. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
• 12.3. Europe
  • 12.3.1. Overview
  • 12.3.2. Oral Complement Inhibitors Key Manufacturers in Europe
  • 12.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 12.3.4. Europe Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
  • 12.3.5. Europe Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
  • 12.3.6. Europe Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
  • 12.3.7. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  • 12.3.8. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3.9. Germany
    • 12.3.9.1. Overview
    • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.9.3. Germany Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.3.9.4. Germany Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.3.9.5. Germany Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.3.9.6. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.3.9.7. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3.10. UK
    • 12.3.10.1. Overview
    • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.10.3. UK Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.3.10.4. UK Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.3.10.5. UK Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.3.10.6. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.3.10.7. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3.11. France
    • 12.3.11.1. Overview
    • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.11.3. France Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.3.11.4. France Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.3.11.5. France Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.3.11.6. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.3.11.7. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3.12. Italy
    • 12.3.12.1. Overview
    • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.12.3. Italy Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.3.12.4. Italy Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.3.12.5. Italy Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.3.12.6. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.3.12.7. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3.13. Spain
    • 12.3.13.1. Overview
    • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.13.3. Spain Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.3.13.4. Spain Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.3.13.5. Spain Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.3.13.6. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.3.13.7. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3.14. The Netherlands
    • 12.3.14.1. Overview
    • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.14.3. The Netherlands Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.3.14.4. The Netherlands Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.3.14.5. The Netherlands Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.3.14.6. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.3.14.7. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3.15. Sweden
    • 12.3.15.1. Overview
    • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.15.3. Sweden Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.3.15.4. Sweden Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.3.15.5. Sweden Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.3.15.6. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.3.15.7. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3.16. Russia
    • 12.3.16.1. Overview
    • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.16.3. Russia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.3.16.4. Russia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.3.16.5. Russia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.3.16.6. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.3.16.7. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3.17. Poland
    • 12.3.17.1. Overview
    • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.17.3. Poland Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.3.17.4. Poland Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.3.17.5. Poland Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.3.17.6. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.3.17.7. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3.18. Denmark
    • 12.3.18.1. Overview
    • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.18.3. Denmark Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.3.18.4. Denmark Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.3.18.5. Denmark Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.3.18.6. Denmark Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.3.18.7. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.3.19. Rest of Europe
    • 12.3.19.1. Overview
    • 12.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.3.19.3. Rest of the Europe Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.3.19.4. Rest of the Europe Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.3.19.5. Rest of the Europe Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.3.19.6. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.3.19.7. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
• 12.4. Asia Pacific (APAC)
  • 12.4.1. Overview
  • 12.4.2. Oral Complement Inhibitors Key Manufacturers in Asia Pacific
  • 12.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 12.4.4. APAC Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
  • 12.4.5. APAC Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
  • 12.4.6. APAC Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
  • 12.4.7. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  • 12.4.8. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4.9. China
    • 12.4.9.1. Overview
    • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.9.3. China Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.4.9.4. China Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.4.9.5. China Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.4.9.6. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.4.9.7. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4.10. India
    • 12.4.10.1. Overview
    • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.10.3. India Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.4.10.4. India Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.4.10.5. India Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.4.10.6. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.4.10.7. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4.11. Japan
    • 12.4.11.1. Overview
    • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.11.3. Japan Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.4.11.4. Japan Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.4.11.5. Japan Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.4.11.6. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.4.11.7. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4.12. South Korea
    • 12.4.12.1. Overview
    • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.12.3. South Korea Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.4.12.4. South Korea Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.4.12.5. South Korea Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.4.12.6. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.4.12.7. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4.13. Australia
    • 12.4.13.1. Overview
    • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.13.3. Australia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.4.13.4. Australia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.4.13.5. Australia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.4.13.6. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.4.13.7. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4.14. Indonesia
    • 12.4.14.1. Overview
    • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.14.3. Indonesia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.4.14.4. Indonesia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.4.14.5. Indonesia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.4.14.6. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.4.14.7. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4.15. Thailand
    • 12.4.15.1. Overview
    • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.15.3. Thailand Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.4.15.4. Thailand Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.4.15.5. Thailand Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.4.15.6. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.4.15.7. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4.16. Philippines
    • 12.4.16.1. Overview
    • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.16.3. Philippines Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.4.16.4. Philippines Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.4.16.5. Philippines Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.4.16.6. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.4.16.7. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4.17. Taiwan
    • 12.4.17.1. Overview
    • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.17.3. Taiwan Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.4.17.4. Taiwan Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.4.17.5. Taiwan Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.4.17.6. Taiwan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.4.17.7. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4.18. Vietnam
    • 12.4.18.1. Overview
    • 12.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.18.3. Vietnam Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.4.18.4. Vietnam Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.4.18.5. Vietnam Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.4.18.6. Vietnam Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.4.18.7. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.4.19. Rest of APAC
    • 12.4.19.1. Overview
    • 12.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.4.19.3. Rest of APAC Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.4.19.4. Rest of APAC Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.4.19.5. Rest of APAC Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.4.19.6. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.4.19.7. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
• 12.5. Latin America (LATAM)
  • 12.5.1. Overview
  • 12.5.2. Oral Complement Inhibitors Key Manufacturers in Latin America
  • 12.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 12.5.4. LATAM Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
  • 12.5.5. LATAM Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
  • 12.5.6. LATAM Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
  • 12.5.7. LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  • 12.5.8. LATAM Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.5.9. Brazil
    • 12.5.9.1. Overview
    • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.5.9.3. Brazil Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.5.9.4. Brazil Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.5.9.5. Brazil Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.5.9.6. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.5.9.7. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.5.10. Mexico
    • 12.5.10.1. Overview
    • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.5.10.3. Mexico Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.5.10.4. Mexico Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.5.10.5. Mexico Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.5.10.6. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.5.10.7. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.5.11. Argentina
    • 12.5.11.1. Overview
    • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.5.11.3. Argentina Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.5.11.4. Argentina Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.5.11.5. Argentina Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.5.11.6. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.5.11.7. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.5.12. Colombia
    • 12.5.12.1. Overview
    • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.5.12.3. Colombia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.5.12.4. Colombia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.5.12.5. Colombia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.5.12.6. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.5.12.7. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.5.13. Rest of LATAM
    • 12.5.13.1. Overview
    • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
• 12.6. Middle East and Africa
  • 12.6.1. Overview
  • 12.6.2. Oral Complement Inhibitors Key Manufacturers in Middle East and Africa
  • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
  • 12.6.5. Middle East and Africa Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
  • 12.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
  • 12.6.7. Middle East and Africa Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
  • 12.6.8. Middle East and Africa Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.6.9. Saudi Arabia
    • 12.6.9.1. Overview
    • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.6.10. United Arab Emirates
    • 12.6.10.1. Overview
    • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.6.11. Israel
    • 12.6.11.1. Overview
    • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.11.3. Israel Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.6.11.4. Israel Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.6.11.5. Israel Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.6.11.6. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.6.11.7. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.6.12. Turkey
    • 12.6.12.1. Overview
    • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.12.3. Turkey Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.6.12.4. Turkey Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.6.12.5. Turkey Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.6.12.6. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.6.12.7. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.6.13. Algeria
    • 12.6.13.1. Overview
    • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.13.3. Algeria Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.6.13.4. Algeria Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.6.13.5. Algeria Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.6.13.6. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.6.13.7. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.6.14. Egypt
    • 12.6.14.1. Overview
    • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.14.3. Egypt Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.6.14.4. Egypt Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.6.14.5. Egypt Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.6.14.6. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.6.14.7. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.6.15. Iran
    • 12.6.15.1. Overview
    • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.15.3. Iran Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.6.15.4. Iran Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.6.15.5. Iran Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.6.15.6. Iran Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.6.15.7. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.6.16. Qatar
    • 12.6.16.1. Overview
    • 12.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.16.3. Qatar Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.6.16.4. Qatar Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.6.16.5. Qatar Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.6.16.6. Qatar Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.6.16.7. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 12.6.17. Rest of MEA
    • 12.6.17.1. Overview
    • 12.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 12.6.17.3. Rest of MEA Market Size and Forecast, By Drug, 2020 - 2033 (US$ Million)
    • 12.6.17.4. Rest of MEA Market Size and Forecast, By Age Group, 2020 - 2033 (US$ Million)
    • 12.6.17.5. Rest of MEA Market Size and Forecast, By Distribution, 2020 - 2033 (US$ Million)
    • 12.6.17.6. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
    • 12.6.17.7. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)

13. Key Vendor Analysis- Oral Complement Inhibitors Industry

• 13.1. Competitive Benchmarking
  • 13.1.1. Competitive Dashboard
  • 13.1.2. Competitive Positioning
• 13.2. Company Profiles
  • 13.2.1. Akari Therapeutics, Plc
  • 13.2.2. Alexion Pharmaceuticals, Inc.
  • 13.2.3. Apellis Pharmaceuticals, Inc.
  • 13.2.4. Biocryst Pharmaceuticals, Inc.
  • 13.2.5. Amgen Inc.
  • 13.2.6. ChemoCentryx, Inc.
  • 13.2.7. Ionis Pharmaceuticals, Inc.
  • 13.2.8. Johnson & Johnson Services, Inc.
  • 13.2.9. Merck & Co., Inc.
  • 13.2.10. Novartis AG
  • 13.2.11. Pfizer Inc.
  • 13.2.12. Regeneron Pharmaceuticals, Inc.
  • 13.2.13. Omeros Corporation
  • 13.2.14. Roche Holding AG
  • 13.2.15. Swedish Orphan Biovitrum AB
  • 13.2.16. Others

14. 360 Degree Analyst View

15. Appendix

• 15.1. Research Methodology
• 15.2. References
• 15.3. Abbreviations
• 15.4. Disclaimer
• 15.5. Contact Us